Biogen continues to expect a gradual launch of the company’s Byooviz (ranibizumab-nuna) biosimilar, following market entry in June, “with more meaningful revenue contribution starting in 2023.”
Biogen Reiterates Byooviz Will Not Be Meaningful In 2022
Launches Outside Of The US Scheduled For Early 2023
Biogen is looking for its ranibizumab biosimilar Byooviz to make a splash in 2023 as it continues to forecast falling biosimilars sales for 2022.
